In December 2024, the adult sons of Marjorie Tingley, an 85-year-old woman living in a dementia care unit, received an urgent message from Vista Grande Villa, a senior living community in Michigan. Administrators warned that their mother posed a serious safety risk to staff. According to behavior logs kept by the facility, Tingley had struck, kicked, or elbowed aides on at least ten days that November while they attempted to assist her with dressing, bathing, toileting, or changing her briefs. The facility requested permission to sedate her. What followed was a bitter dispute between her sons and Vista Grande Villa that stretched into the new year, centering on one of the most controversial practices in long-term care: the use of antipsychotic drugs to calm agitated dementia patients.
The medications at the heart of this conflict carry serious risks. The U.S. Food and Drug Administration requires drugmakers to place warnings on these potent treatments, cautioning that they raise the likelihood of death among older adults diagnosed with Alzheimer's disease and related conditions. Despite these dangers, the drugs remain a common tool in care facilities for managing behavioral symptoms that staff may struggle to handle through other means. The Tingley case illustrates the difficult, often painful decisions that families and legal guardians must make when a loved one's dementia leads to aggression or resistance to care.
The scale of the issue is considerable. More than 5 million people enrolled in Medicare have received a dementia diagnosis, according to data cited by NPR. Even after a 14-year federal effort to curb the use of psychotropic medications in nursing homes and similar settings, roughly one in four Medicare beneficiaries with dementia are potentially inappropriately prescribed antipsychotics and other brain-altering drugs, according to a study published in JAMA. These medications can trigger delirium, contribute to falls, and lead to hospitalizations, compounding the health problems they are meant to address.
The federal campaign to reduce psychotropic use began with the goal of improving safety and quality of life for dementia patients. Regulators and advocates have long argued that non-drug approaches—such as behavioral interventions, environmental adjustments, and personalized care plans—should be tried first. Yet the persistence of high prescribing rates suggests that such alternatives are not always available or prioritized, particularly in facilities facing staffing shortages, time pressures, and the challenging reality of caring for people whose condition can make them combative or difficult to assist.
For family members, the decision to medicate is rarely simple. On one side, there is the immediate concern for the patient's safety and the safety of caregivers. On the other, there is the worry that sedating medications will dull a loved one's remaining cognitive function, hasten decline, or even shorten life. The Tingley family's resistance to Vista Grande Villa's request reflects a broader tension that plays out in care facilities across the country, where administrators must balance regulatory guidance, staff well-being, and resident rights.
Vista Grande Villa's behavior logs became a central piece of evidence in the dispute. The records documented specific incidents in which Tingley allegedly hit, kicked, or elbowed aides during personal care routines. For the facility, these logs justified a request for chemical intervention. For her sons, the logs may have represented a failure of the care environment to adapt to their mother's needs without resorting to medication. The disagreement persisted into the new year, highlighting how difficult it can be to resolve such conflicts when families and providers hold fundamentally different views on appropriate treatment.
Antipsychotic medications were not originally developed for dementia. They are approved to treat conditions such as schizophrenia and bipolar disorder, but they are frequently prescribed off-label to address agitation, aggression, and psychosis in dementia patients. This practice persists even though the FDA has not approved these drugs for dementia-related behaviors, and despite boxed warnings about increased mortality. The gap between approved use and real-world practice leaves families and physicians navigating uncertain territory, often without clear guidelines tailored to individual cases.
The JAMA study's finding that one in four Medicare beneficiaries with dementia may be inappropriately prescribed these medications points to systemic issues rather than isolated incidents. Inappropriate prescribing can stem from inadequate training in dementia care, insufficient staffing to implement behavioral strategies, or pressure to resolve disruptive behaviors quickly. While some prescriptions may be clinically justified, many are not, exposing residents to risks that outweigh potential benefits. Federal efforts to reduce such prescribing have achieved only limited success over more than a decade.
The Tingley case also raises questions about the rights of dementia patients and the authority of guardians and family members. When a person loses the capacity to make medical decisions, others must step in, but their choices may conflict with a facility's recommendations. In Michigan, as elsewhere, there is no simple legal formula for resolving these disputes. The outcome can depend on state regulations, the willingness of providers to explore alternatives, and the persistence of family members in advocating for their loved one's preferences and dignity.
Non-drug approaches to agitation in dementia do exist. They include redirecting attention, modifying the environment to reduce triggers, establishing consistent routines, and training staff in communication techniques. Some facilities have successfully reduced antipsychotic use by adopting person-centered care models. However, these approaches require time, staffing, and institutional commitment—resources that are not evenly distributed across long-term care settings. When they are absent, medication can become the default response, even when families object.
The emotional toll on families like the Tingleys can be severe. Adult children often find themselves caught between wanting their parent to be safe and comfortable and fearing that sedation will erase what remains of their personality. They may feel pressured by facility staff who describe their parent as a danger to others. They may also lack the medical expertise to challenge a physician's recommendation. These dynamics can turn a care decision into a conflict, with the patient's best interests at the center of a dispute neither side can easily resolve.
Federal regulators have acknowledged the problem for years. The 14-year campaign to reduce psychotropic use in nursing homes has included public reporting of prescribing rates, training initiatives, and guidance encouraging non-pharmacological interventions. Yet change has been slow. The JAMA study's findings suggest that progress has stalled or that earlier gains have not reached all populations. For policymakers, the challenge is to strengthen oversight without creating barriers to appropriate care for patients who genuinely need medication to function or remain safe.
Vista Grande Villa's request to sedate Marjorie Tingley was not unusual in itself. Facilities frequently seek consent from families or guardians when behavior becomes difficult to manage. What made the case notable was her sons' refusal and the prolonged struggle that followed. Their stance forced the facility to confront whether it could meet Tingley's needs without the drugs it had proposed. The outcome of that struggle, as reported by NPR, underscores the wrenching choices that families and guardians face when dementia transforms a loved one's behavior and care becomes a source of conflict rather than comfort.
Ultimately, the Tingley case reflects a larger national conversation about how society cares for people with dementia. The widespread use of sedating medications despite federal warnings and efforts to reduce them suggests that current systems are not adequately supporting either patients or caregivers. Families want to protect their loved ones from unnecessary chemical restraint, while facilities want to protect staff and other residents from harm. Bridging those goals will require investment in better staffing, training, and alternative therapies—and a recognition that the status quo carries its own significant costs.
(0)